Particulate platforms capable of delivering multiple actives while providing diagnostic features have gained considerable interest over the last few years. In this study, magnetic polymer yolkshell particles (YSPs) were engineered using a tri-needle coaxial electrospraying technique enabling dual-mode (ultrasonic and magnetic resonance) imaging capability with specific multidrug compartments via an advanced single-step encapsulation process. YSPs comprised magnetic Fe 3 O 4 nanoparticles (MNPs) embedded in the polymeric shell, an interfacing oil layer and a polymeric core (i.e. composite shell-oil interface-polymeric core). Ultrasound backscatter signal frequency was modulated through YSP loading dosage, and both T 1 and T 2 weighted MRI signal intensities were shown to reduce with increasing MNP content (YSP outer shell). Three fluorescent dyes (selected as model probes with varying hydrophobicities) were co-encapsulated separately to confirm YSP structure. Probe release profiles were tuned by varying power or frequency of an external auxillary magnetic field (AMF, 0.7 mT (LAMF) or 1.4 mT (HAMF)).
ABSTRACT:
Particulate platforms capable of delivering multiple actives while providing diagnostic features have gained considerable interest over the last few years. In this study, magnetic polymer yolkshell particles (YSPs) were engineered using a tri-needle coaxial electrospraying technique enabling dual-mode (ultrasonic and magnetic resonance) imaging capability with specific multidrug compartments via an advanced single-step encapsulation process. YSPs comprised magnetic Fe 3 O 4 nanoparticles (MNPs) embedded in the polymeric shell, an interfacing oil layer and a polymeric core (i.e. composite shell-oil interface-polymeric core). Ultrasound backscatter signal frequency was modulated through YSP loading dosage, and both T 1 and T 2 weighted MRI signal intensities were shown to reduce with increasing MNP content (YSP outer shell). Three fluorescent dyes (selected as model probes with varying hydrophobicities) were co-encapsulated separately to confirm YSP structure. Probe release profiles were tuned by varying power or frequency of an external auxillary magnetic field (AMF, 0.7 mT (LAMF) or 1.4 mT (HAMF)).
In addition, an "inversion" phenomenon for AMF-enhanced drug release process was captured and is reported. Low YSP cytotoxicity (5mg/ml) and biocompatibility (murine, L929) was confirmed. In summary, magnetic YSPs demonstrate timely potential as multifunctional theranostic agents for dual-imaging modality and magnetically controlled co-active delivery.
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INTRODUCTION
Particles exhibiting combined diagnostic (e.g. imaging) and therapeutic (controlled or triggered active release) functions are extremely valuable to address several global healthcare challenges; with extensive recent efforts focusing on tumor targetting, personalized medicine and biomedical engineering. [1] [2] Such particles enable a single carrier system to provide real-time disease diagnosis in-vivo as well as fine-tune active release at a specific location in timely fashion. This multi-faceted approach, in lieu, has propelled them as emerging paradigms for clinical practice. [3] [4] [5] Furthermore, the functionality of such particles goes beyond image-guided drug delivery; in that rapid assessment and treatment of disease is accomplished at an early stage whilst minimizing unwanted cytotoxic side-effects often arising from conventional strategies. [6] [7] Magnetic resonance imaging (MRI) is a pain-free and safe diagnostic procedure that has numerous advantages over other routine imaging methods including excellent anatomic detail, exquisite soft tissue contrast, high spatial resolution and multi-planar imaging capacity. [8] [9] MRI signal is dependent on longitudinal (T 1 ) and transverse (T 2 ) proton relaxation times of water (mainly) and therefore; differences arising in these values provide variable contrast in images.
MRI contrast agents are able to decrease T 1 and T 2 relaxation times, and subsequently improve contrast between normal and diseased tissues. [10] [11] Furthermore, because of their interaction with magnetic fields, contrast agents have also been used to control active agent release from coencapsulated or co-embedded systems via an auxiliary magnetic field (AMF). 12 In contrast, ultrasound (US) is a well-established and widely used clinical imaging modality. This technique provides real time imaging, particularly for blood flow, and several advantages relating to cost effectiveness, portability and high patient acceptability have led to its preference (globally) in various clinical settings. 13 While both of these imaging modalities are essential in present and emerging diagnostic technologies, MRI and US have their own limitations. For instance, MRI is not applicable for real-time imaging and also requires a relatively longer time period for image acquisition. 9 US imaging provides lower resolution and penetration depth, which hinders its ability to discriminate between superficial and echogenic structures. 8 In this regard, the development of a dual-imaging modality technique, combining both MRI and US, will be timely and enables much needed advance from either platform. Moreover, to maximize the merits of an integrated imaging technique; design and construction of effective and viable contrast agents suitable for both modalities will be of significance. 7, 9 In recent times, encapsulation and delivery of multiple drugs from a single dosage form platform is considered to be crucial for patient compliance and advanced therapies. For example, combination of anti-inflammatory and anti-cancer drugs in a single cargo is promising for cancer therapy since targeting inflammation, in addition to restricting replication, further reduces tumor development and progression. 14 Therefore, co-encapsulation of two or more actives has potential to deliver synergistic therapeutic effects and reduced side-effects. 15 Furthermore, the possibility to co-encapsulate hydrophilic and hydrophobic drugs in a single dosage form is ideal for drug dispersibility, active release and therapeutic impact 16 . Several co-formulation strategies become resticted due to complexities surrounded active hydrophobicity, formulation, retention and delivery.
Developments in synergistic therapies (multi-drug dosing) have yielded numerous explorations and formulations which provide multiple active delivery from a single cargo. [17] [18] One such area of focus has centered on encapsulated polymeric particulate systems; with conceptual designs demonstrated in bi-layer, multi-layered and several other complex systems. [19] [20] [21] Among all polymeric particulate formats with compartmentalized (interior) structures, yolkshell particles (YSPs) appear least explored although they display unique features and physical properties; including low densities, large surface areas and excellent loading capacities. 22 Limited data shows the design and development of functionalized YSP interior core and outer shell have potential to enhance drug delivery, although the vast majority of related research to date has focused on inorganic materials (including silica and carbon based). 23 In this regard, polymer based YSPs will afford improved biodegradability, biocompatibility and will also be more favorable economically. Current design and preparation of YSPs involve numerous and complex steps, elevated engineering temperatures and micron-scaled etching techniques. 23 In this study, polymer based magnetic YSPs were engineered with the ability to host multiple probes (as model chemical agents). Complex particle engineering was achieved using tri-needle co-axial electrospraying which is a single step process. Poly(ε-caprolactone) (PCL) was selected as the matrix for both core and the shell materials because of its accepted biocompatibility and related drug permeability. 19 Silicone oil was adopted as the interfacing-layer due to its moderate viscosity. 24 In order to demonstrate co-encapsulation (in seperate compartments) and delivery, Nile blue (NB) and acridine yellow (AY) were selected as model hydrophilic probes and Sudan red G (SRG) was selected due to its hydrophobic nature. Magnetic nanoparticles (MNPs) (Fe 3 O 4 ~20 nm in diameter) were encapsulated into YSPs (shell layer) to enable magnetic properties.
YSP composition, interior structure, biocompatibility, dual imaging modality and controlled multi-probe release from therein (with and without an external AMF trigger) were investigated.
MATERIALS AND METHODS

Materials
Poly(-caprolactone) (M w =4.5x10 3 Figure 1a is a schematic illustration of the tri-needle coaxial electrospray system used for YSP synthesis. The nozzle system comprises a set of three stainless steel needles (into one concentrically aligned nozzle spraying cylindrical head); three syringe pumps (KD Scientific KDS100, USA), a high voltage power supply (Glassman high voltage Inc. series FC, USA) and a metallic ground ring electrode (diameter~ 5 cm). For nozzle assembly, the three stainless steel needle capillaries possessed inner and outer diameters of 2.85 mm and 2.26 mm for the outer capillary, 1.60 mm and 1.07 mm for the central capillary, and 0.50 mm and 0.31 mm for the inner capillary, respectively. Media inlets of the three capillaries were connected to the corresponding syringes using silicone tubing. The corresponding liquids were injected into capillaries by independently controlled syringe pumps. The processing nozzle was connected to the high voltage power supply and the metallic ground electrode ring was located directly below the nozzle assembly (5 mm). The power supply was used to provide a static electric field between the outlet of nozzle assembly and the ground electrode. A CCD camera (Baumer TXG02C, Germany) was connected to image capture hardware (PC) and was used to monitor real-time jetting behavior of atomized spray (formed using the tri-needle co-axial electrospray system) for stable and near-uniform particle production. The applied voltage was maintained at 10 kV for all experiments. All YSPs were fabricated using flow rates of 10 ml/h, 2.5 ml/h and Formulation, formation and compartments of probe loaded magnetic yolk-shell particles.
Fabrication of Yolk-Shell Particles (YSPs) via tri-needle co-axial electrospray
Characterization
Optical, fluorescence and scanning electron microscopies (SEM) were used to observe size, surface morphology and interior structure of the YSPs. For optical and fluorescent micrographs, particles were collected directly onto microscopic glass slides and observed using an optical microscope (Pheonix BMC503-ICCF, China) and an inverted fluorescence microscope (Nikon, Ti-S, Japan), respectively. For SEM analysis, YSPs were sprayed on aluminium film and then mounted on to a metallic stud using double-sided conductive tape for sputter coating. A thin layer of gold under vacuum (Ion Sputter MC 1000, Hitachi, Japan) was deposited for 90s. SEM images were obtained using a field emission-scanning electron microscope (FE-SEM, FEI Quanta 650 FEG, Hillsboro, Oregon, USA). The diameters of YSPs were analyzed using imageJ software (National Institute of Health, USA) directly from electron micrographs. YSP stability was assessed in two environments; in air (i.e. storage) and in PBS. YSPs were observed for changes to their surface morphology and structure at 1, 3, 5 and 7 days using SEM.
Sample composition was determined using Fourier Transform Infra-Red (FTIR) spectroscopy.
Samples were prepared by mixing 2 mg of selected particles with 200 mg of KBr medium by grinding and then compressing the resulting powder into transparent pellets (pressure of 12 MPa). 25 Pellets were then scanned with FTIR (IR Affinity 1, Shimadzu, Japan) and the spectrum was obtained at a resolution of 4 cm -1 ranging from 4500 to 500 cm -1 . Each spectrum was obtained using 20 scans. X-ray diffraction (XRD) was used to confirm successful encapsulation of MNPs in YSPs, spectra were recorded with a diffractometer (X'pert PRO, Panalytical, Netherlands) equipped with standard Cu Kα radiation source (λ = 1.5405 Å) and
scanned within 2θ range of 10-90° at a step size of 0.026°. The operating voltage and current were 40 kV and 40 mA, respectively. Sample magnetization curves were obtained using a vibration sample magnetometer (VSM Mini-CFM measurement system, Cryogenic Ltd., UK) at 300K under a reciprocating altered magnetic field (-30000 to 30000 Oe), and saturation magnetization was obtained from hysteresis loops.
In-vitro MRI evaluation.
Imaging data was acquired using a 3 Tesla MRI scanner (Magnetom Prisma, Siemens Healthcare, Erlangen, Germany) through a 20-channel head-neck coil. MRI measurements for two experimental groups and a control sample were obtained. For the first group, phantoms contained 4 mg of particulate samples at various MNP:PCL outer layer mass ratios (0, 25, 50, 75 mg/g). The second group comprised samples with identical MNP:PCL mass ratios (0.5, 1, 2, 4 mg). 4 mg of pure MNPs were used for control experiments. For phantom preparation, 1g of agar was added to 100 ml ultrapure water and the mixture was subsequently boiled for 30s and cooled. This cycle was repeated until a homogeneous agar gel was obtained, which was then allowed to cool further in atmosphere to 40 C. All phantoms to be used for MRI were then prepared by mixing particulate samples with 10 ml of the pre-prepared agar gel and 2 ml 5 w/v% SDS aqueous solution (to improve sample wetting and enhance phantom uniformity 26 ). Sample-gel mixtures were stirred thoroughly to form a uniform suspension, and were then poured into a 15 ml centrifuge tube. Pure agar phantoms (without samples) were also fabricated for control experiments. automatically calculated by the system using exponential curve fitting, and mean values were calculated in the regions of interest (ROI), selecting ~50% of total area at the cross section's center.
Acoustic characterization
The setup for acoustic experiments is shown in Figure 2 , as utilised in a previous report. 27 Pre-weighed particles (0, 2 and 10 mg) with an outer layer MNP:PCL mass ratio of 75 mg/g were suspended using 20 ml ethanol in a plastic container (2.8 cm in diameter and 3.5 cm in depth). A 5 MHz ultrasonic transducer (1.6 cm in diameter and 3 cm in depth) was vertically submerged into the suspension (serving as both transmitter and reciever) and was connected to a pulser/receiver (5073PR, Olympus Inc., Japan). All signal data from the pulser/receiver was acquired and stored using an oscilloscope (200MHz bandwith, WaveSurfer 3024, Teledyne LeCroy, USA). Parameters for acoustic experiments were kept constant (PRF=200 Hz, Energy=2, Damping=2, Gain=20 dB) and data was processed using Matlab 2013b
(The Mathworks Inc., Natick, USA). 
Probe loading capacity and encapsulation efficiency
The loading capacity (LC) of selected probes was determined as the quantity of probe encapsulated within YSPs and was calculated using 
In-vitro probe release and AMF application
Probe release profiles from various YSP layers were investigated in vitro. For this, 30 mg of NB and AY loaded (or alternatively SRG) YSPs were suspended using 10 mL release medium, respectively, which comprised PBS (pH=7.2) and 0.5 w/v% SDS to maintain sink conditions 29 in a 10mL glass vial. Probe release in static or AMF triggered environments at the ambient temperature (~23.5 C) were assessed. A strong magnet was applied in close proximity to the base of sample hosting vials to completely separate YSPs from test-medium; and then 4 mL of supernatant was collected. This procedure was performed at pre-determined time intervals.
Supernatant concentration was determined using UV-Vis spectroscopy (UV-2600 spectrophotometer, Shimadzu, Japan). 12 Removed analyte samples were replaced with 4 mL of fresh release medium (PBS). For AMF trigger application, a copper solenoid coil (45 turns) was laced around a plastic tube and driven by a power amplifier (HFVA-42, Foneng Science and Technology Co., Ltd., Nanjing, China). A functional signal generator (AFG1022, Tektronix, USA) was used to produce a small sinusoidal signal, which was then amplified to generate an AMF around the coiled tube. The sample hosting vial was placed in the coiled tube's hollow core, which ensured YSPs were subjected to the applied AMF. All other conditions were constant. The effect of both frequency and power on probe release was investigated. All experiments were performed in triplicate.
In order to examine potential thermal impact (arising from AMF generation) on YSPs, a Ti32 thermal camera (Fluke Corporations, Seattle, USA) was deployed to image the process at predetermined time intervals. Data was analyzed using SmartView software to extract temperature field distribution, which was subsequently used to calculate mean temperature.
In vitro cell culture and biocompatibility
YSP biocompatibility and potential cytotoxic effects were evaluated using in vitro cell culture.
L929 mouse fibroblasts were propagated in MEM medium with 10% heat-inactivated FBS and 1%
(v/v) antibiotic-antimycotic in a petri dish which were incubated at 37 °C in humidified CO 2 (5%) environment.
For biocompatibility assessement, cells were incubated for 24 h. The culture medium was replaced with 3 mL of fresh medium containing magnetic YSPs at varying concentrations (0, 1 and 5 mg/ml). For this, an YSP outer shell MNP:PCL mass ratio of 75 mg/g was selected. After 24 h, cells were visualized using fluorescent counterstaining with rhodamine-phalloidin and DAPI to observe morphology and confirm cellular state. Treated cells were washed with PBS three times and fixed with 4% paraformaldehyde for 30 min. Cell permeabilization was achieved using 0.1% Triton X-100 for 5 min followed by washing with PBS, and the procedure was four jetting modes are encountered: dripping mode, coning mode, stable cone-jet mode and multi-jet mode 24 . The stable cone-jet mode is optimal and is ideal for near-uniform YSP production with intact shell morhology and a well-defined interior structure (obtained at ~10 kV) as shown in Figure 1b. Figure 1c shows YSP formulation, architecture and compartments.
Three media were infused into the tri-needle coaxial nozzle and stable jetting was observed.
Interestingly, the compound jet comprised polymer solutions at inner and outer flows;
sandwiching the oil in the central layer compartment. The jetting stability was reminiscent to those osberved for single and conventional two-needle coaxial electrosprays. This indicated YSPs would possess near uniform structures with neat core-shell encapsulation.
Particle structure and morphology
The external morphology and interior arrangement of YSPs were assessed comprehensively. highlights a ruptured YSP which may have arisen due to sporadic MNP agglomeration which impedes polymer layering ability during processing on the micron scale. This, however, confirmed the anticipated yolk-shell structure (particle in particle) as evidenced in the micrograph. Figure 3f is an electron micrograph showing the cross section of a YSP embedded in epoxy resin. In this instance, the core shell merged with the epoxy resin and the void space between the core and the outer shell indicates the existence of the interfacing oily layer. YSP morphology for samples assessed in air and PBS at 1, 3, 5 and 7 days, respectively, is shown in 
Magnetic properties
XRD was used to confirm successful encapsualtion of MNPs in YSPs. Figure 5(a compared to high speed centrifugation and precipitation, which may also potentially lead to an increase in release from the carrier system 32 ). Furthermore, the ability to move and direct YSPs, using a small yet powerful magnet, indicates clear potential for localised drug delivery and targeting. 
In-vitro MRI evaluation
To evaluate YSP potential as an MRI contrast agent, a series of agarose phantoms were prepared. Two main factors were investigated. In the first instance, different quantites of YSPs (2)) and T 1 -weighted MRI images (rows (3) to (4)). (b) and (c) are linear fits of 1/T 1 for phantoms comprising 4 mg of particle samples with varying MNP:PCL shell ratios and varying overall particle quantities using a shell MNP:PCL ratio of 75 mg/g. (d) T 2 maps (row (1) to (2)) and T2-weighted images (row (3) to (4)). (e) and (f) are linear fits of 1/T 2 for phantoms comprising 4 mg of samples with varying shell MNP: PCL ratios and particle quantities (using a fixed shell MNP:PCL ratio of 75 mg/g).
In vitro acoustic characterization
To evaluate YSP potential as an US contrast agent, acoustic properties of magnetic YSPs (75 mg/g MNP:PCL ratio in the outer shell) at various concentrations (0, 2 and 10 mg/ml) were measured using experimental setup illustrated in Figure 2 . The frequency spectra demonstrates acoustic performance is enhanced by increasing YSP concentration in the test sample near the centre frequency, as shown in Figure 7 . Here, ethanol was used as the test medium instead of PBS (or ultrapure water) because of improved YSP dispersibility in the solvent compared to other media. 27 Figure 7 . Echo signal frequency spectra of suspensions with varying particle loading volumes in ethanol.
Multiple in-vitro probe loading and release from various particle compartments
The from magnetic YSPs were comprehensively studied. Over the last two decades, explorations into synergistic chemotherapies (utilizing two or more actives) to treat various types of cancers have broadened, and numerous efforts have focused on the role and development of advanced carriers systems. [17] [18] [33] [34] For drug carrier design; hydrophilicity of incorporated active is a crucial factor, not only for matrix dispersibility but to achieve ideal therapeutic release. 16, 35 Therefore, development of advanced carrier systems capable of delivering active(s) with varying hydrophilicities is extremely valuable. In addition to delivery, a process which enables encapsulation of a broad range of chemical agents is also desirable due to formulation barriers.
In order to demonstrate hydrophobic and hydrophilic agent encapsulation; single-step coencapsulation (and subsequent co-delivery) from a single carrier was demonstrated. NB and AY probes were selected as model hydrophilic agents and SRG was chosen as the hydrophobic component. To ensure accuracy for release measurments (overcoming any issues arising from key overlapping characteristic peaks), NB & AY probe loaded YSPs (and SRG loaded YSPs)
were fabricated independently. For NB and AY co-loading, NB was dispersed into the outer polymeric shell and AY was incorporated in to the inner core. For SRG loading into YSPs, the compound was mixed with SLO in the interfacing oily layer, as a single agent delivery system.
A schematic illustration and corresponding UV-vis spectra from the two deployed samples is shown in Figure 8a and b. The spectrum in Figure 8a shows the maximum absorption peaks of NB and AY, which were identified at 637 and 460 nm, respectively. (Figure 9d) , is enhanced compared to the control group when magnetic YSPs are exposed to an external AMF.
This is attributed to AMF interaction with co-encapsulated MNPs, which produces heat due to hysteresis, Néel and Brownian relaxation upon exposure to AMF 36 . In addiiton, probe release is more pronounced when the higher AMF power setting is deployed (HAMF, 1.4 mT). For hydrophobic probe (SRG, Figure 9c ) the greaest release rate is observed at the HAMF. However, the lowest SRG release rate was obtained using low power AMF setting (LAMF, 0.7 mT); and was more sustained than the control group (no AMF trigger deployed). It is interesting to note that SRG release behavior is different to other probes under an AMF, with contrasting hydrophillicities (e.g. NB and AY). AMF action leads to magnetic YSP compression and exertion against the particle shells surface, which in turn impacts adjacent YSPs. 32 In this regard, for oil-phase compartment, the volume of encapsulated central medium is "locked" in the YSP structure and inhibited from direct contact with the surface. Therefore, although the temperature of intra-particle oil-phase may increase moderately (from 23.5 to 28.0 C) upon exposure to LAMF, the release of hydrophobic probe is actually impeded by micron-scaled barrier function.
In addition, magnetic compression induced "inversion", which is defined here as reduced drug release rate phenomenon upon AMF application, was observed and is highlighted in Figure 9b- 
Here, M t /M ∞ is the fraction released drug at time t, k is the release rate constant, and n is the release exponent. In this model, the value of n is used to postulate the release mechanism. For a spherical matrix, n ≤0.43 corresponds to Fickian diffusion, 0.43 < n < 0.85 to anomalous transport, n = 0.85 to case II (relaxational) transport, and n > 0.85 to super case II transport. Data were plotted as log cumulative percentage drug release versus log time for the first 4 h of probe release (the fraction of released probe ranged from 45 to 65%). The fitting parameters obtained from Korsmeyer-Peppas model are displayed in Table 1 . Table 1 Fitting parameters for probe release from yolk shape particles.
Drug-Mode
Korsmeyer-Peppas Model 39 In contrast, although AY and SRG probes are also affected by generated heat, resulting stress towards the shell is lower due to encapsulation in non-MNP compartments. The impact of varying AMF frequencies (20, 40 and 80kHz) on probe release profiles were also investigated to further confirm "inversion" aspects in the first 2 h (Figure 10a-c) . NB and AY probes exhibit "inversion" phenomena at 20, 40 and 80 kHz, while this was only present at 20 KHz for SRG. The finding indicates the "inversion" is a universal mechanism regardless of probe hydrophilicity. The real time in-situ temperature of particulate samples exposed to HAMF is shown in Figure 10d . Thermal graphs demonstrate near identical temperatures for all release media hosting various YSP samples. The temperature increases rapidly during the first 2 h (23.5 to 31 C) and then a gradual increment is observed, eventually reaching 33 C over the next 4 h. This confirmed MNPs induce heat upon exposure to AMF, which is an important factor in enhancing model probe release. 
Cell culture and fluorescent microscopy
To assess biocompatibility, cells were incubated with YSPs for 24 h at various concentrations (0, 1 and 5 mg/ml). For this YSPs possessing a shell MNP:PCL ratio of 75 mg/g MNPs were fixed and counterstained using DAPI for nuclei and rhodamine-phalloidin for cytoskeleton.
Fluorescent images are shown in Figure 11 , which indicate negligible cytotoxicity. Probe loaded YSPs were not assessed due to their fluoresecing nature and their well documented toxicity. 
Cell viability
Cells incubated with YSP samples (using various particle concentrations and incubation times)
were quantitatively assessed using CCK-8 assay. As shown in Figure 12 , YSPs exihibit negligible toxicity toward cells and a slight improvement in cell viability at 4, 8 and 24 h incubation times was observed when compared to the control group (culture medium alone), indicating excellent biocompatibility. However, at an incubation time of 24 h, cell viability at a concetraion of 5 mg/ml is lower than 1 mg/ml. This is ascribed to degradation of PCL into toxic ε-caproic acid. 40 
